Highlights Jun 1 - Jun 7, 2026
new every Sunday
This week brought sharper scrutiny of psychedelic medicine's evidence and safety, alongside legal rulings that may widen access. Psychiatry's cautious engagement shows the field moving toward implementation without resolving core clinical and ethical questions.
-
01
UK woman seeking access to psilocybin therapy wins key human rights court ruling that forces a judicial review of medicine access and end-of-life care
A UK human rights ruling forces judicial review of psilocybin access for end-of-life distress, with implications for compassionate care.
-
02
Court overturns legal aid refusal in psilocybin post-trial case, allowing a patient to challenge denied access to continued treatment after a clinical study ended
A court reopened a patient's bid for post-trial psilocybin, exposing gaps in continuity of care after psychedelic studies end.
-
03
Psychedelics re-enter mainstream psychiatry at the American Psychiatric Association meeting amid clinical promise, professional caution, and tensions over evidence and implementation
At the APA meeting, psychiatrists weighed psychedelic promise against unresolved issues in evidence, safety, training, and delivery.
-
04
Can MDMA cure PTSD? A new review finds the evidence is not yet strong enough to support cure claims and highlights unresolved safety, bias, and trial-design concerns
A review finds MDMA can reduce PTSD symptoms but says cure claims outrun evidence on blinding, safety, remission, and durability.
-
05
Hallucinogen use is linked to a small increase in heart valve disease risk, with stronger associations in women and no clear evidence of severe dysfunction
US survey data link hallucinogen use to a modest rise in diagnosed valve disease, but cannot establish cause or substance-specific risk.
-
06
Review zu Psychedelika bei Borderline-Stoerung - vorhandene Evidenz, Risiken, therapeutische Chancen und offene Fragen fuer Forschung und klinische Praxis
A review maps scant evidence and heightened risks for psychedelic treatment in borderline personality disorder, including suicidality.
-
07
Psychedelika und Modellpsychose - eine Studie prueft, ob Halluzinogene Schizophrenie wirklich nachbilden oder ein eigenes neuropsychologisches Muster zeigen
A study questions whether psychedelic states model schizophrenia, comparing differences in perception, cognition, insight, and meaning.